**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

A man in his 70s developed livedoid reaction during treatment with azithromycin, furosemide, hydroxychloroquine, meropenem and piperacillin/tazobactam \[*routes and dosages not stated*\]. The man received azithromycin and hydroxychloroquine as off-label for COVID-19 management protocol.

The man, who had well-controlled hypertension, presented to the emergency department with a 3-day history of progressive weakness and tachypnoea and a 4-day history of rash. He had not commenced any new medications in the previous month, and did not have a recent travel history outside the city. His cutaneous examination was remarkable for reticular, partially blanching erythematous patches and plaques with non-blanching purpuric borders on the lower back and abdomen. He was subsequently diagnosed with COVID-19. He was intubated and was transferred to the ICU for further treatment. Over the initial 7 days of his ICU course, his skin eruption gradually ameliorated with no directed treatment. He completed a 5-day course of off-label treatment with azithromycin and hydroxychloroquine per protocol. He also received furosemide, meropenem and piperacillin/tazobactam. However, despite supportive care, his condition deteriorated continuously; even with maintaining cardiac output and BP, he had ischaemic renal injury, necessitating haemodialysis. Laboratory evidence revealed worsening coagulopathy. On day 10 of admission, after the initial eruption had resolved, he underwent a rotational thromboelastometry study to evaluate the hemostatic properties of the patient\'s blood, and it was indicative of a hypercoagulable state. Therefore, he was initiated on heparin \[unfractionated heparin\]. On day 14 of admission, he developed prominent white scars in the same location as the prior livedoid reaction on an erythematous background \[*duration of treatment to reaction onset not stated*\]. At this point, he was evaluated by dermatology department. It was postulated that the new eruption was likely an exanthema secondary to the medications he had received while hospitalised. Furosemide, hydroxychloroquine, meropenem, piperacillin/tazobactam and azithromycin were considered as potential culprits.The eruption was not biopsied at the time due to a severe shortage of personal protective equipment in the city area. At the time of this report, he remained in the ICU for 2 months \[*outcome not stated*\].
